Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial

BACKGROUND: Ilorasertib (ABT-348) inhibits Aurora and VEGF receptor (VEGFR) kinases. Patients with advanced solid tumours participated in a phase 1 dose-escalation trial to profile the safety, tolerability, and pharmacokinetics of ilorasertib. METHODS: Ilorasertib monotherapy was administered at 10–...

Descripción completa

Detalles Bibliográficos
Autores principales: Maitland, Michael L., Piha-Paul, Sarina, Falchook, Gerald, Kurzrock, Razelle, Nguyen, Ly, Janisch, Linda, Karovic, Sanja, McKee, Mark, Hoening, Elizabeth, Wong, Shekman, Munasinghe, Wijith, Palma, Joann, Donawho, Cherrie, Lian, Guinan K., Ansell, Peter, Ratain, Mark J., Hong, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931107/
https://www.ncbi.nlm.nih.gov/pubmed/29551775
http://dx.doi.org/10.1038/s41416-018-0020-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931107/
https://www.ncbi.nlm.nih.gov/pubmed/29551775
http://dx.doi.org/10.1038/s41416-018-0020-2

Ejemplares similares